Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
4(36%)
Results Posted
100%(6 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
5
45%
Ph phase_3
5
45%

Phase Distribution

0

Early Stage

5

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
5(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Recruiting4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 25 (50.0%)
Phase 35 (50.0%)

Trials by Status

recruiting436%
completed655%
terminated19%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT04557462Phase 3

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Recruiting
NCT06934967Phase 3

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Recruiting
NCT03955445Phase 3

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Recruiting
NCT04578834Phase 3

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Completed
NCT06931691

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

Recruiting
NCT02534909Phase 2

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed
NCT04154787Phase 2

Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

Terminated
NCT04558918Phase 3

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Completed
NCT03896152Phase 2

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed
NCT03832114Phase 2

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Completed
NCT03373461Phase 2

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11